Endothelial stem cell therapy - CellProThera

Drug Profile

Endothelial stem cell therapy - CellProThera

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CellProthera
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Endothelial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myocardial infarction

Most Recent Events

  • 15 Sep 2014 Preclinical trials in Myocardial infarction in France (Intramyocardial)
  • 15 Sep 2014 CellProThera plans a phase I/IIb trial for Myocardial infarction in United Kingdom and France
  • 06 Mar 2014 Protheracytes® receives Advanced Therapy Medicinal Product designation from the EMA for Myocardial infarction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top